Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Opportunity:
As Director, Translational Sciences, you will be a key member of Translational Research, reporting to the Vice President of Translational Research focusing on:
Lead the scientific strategy and execution of the Translational Research Assay Core, ensuring delivery of high-quality, innovative assays supporting discovery and translational programs.
Establish and continuously evolve assay platforms that enable biomarker discovery, pharmacodynamic assessments, mechanism-of-action studies, and translational hypothesis testing.
Drive exploratory translational research aimed at understanding mechanisms of sensitivity, intrinsic resistance, and acquired resistance across the Revolution Medicines portfolio.
Develop and execute mechanistic studies using patient-derived samples, preclinical models, and emerging technologies to generate actionable biological insights.
Identify novel therapeutic vulnerabilities and rational combination strategies based on clinical and preclinical findings.
Translate observations from clinical studies into research hypotheses that inform target discovery, drug discovery, and translational strategies.
Foster seamless bidirectional translation between clinical observations and discovery research.
Apply functional genomics, single-cell and spatial approaches, and complementary molecular and cellular methods to generate decision-enabling data.
Partner with computational scientists to integrate multi-omic datasets with functional biology and generate mechanistic insights.
Cross-functional Leadership: Partner across Research, Translational Medicine, Bioinformatics, and Clinical Development to integrate findings into biomarker and development strategies.
Responsibilities
Scientific Leadership & Execution: Design, prioritize, and interpret rigorous studies using clinically relevant models and patient-derived materials to address key translational questions.
Reverse Translation & Resistance Biology: Convert patterns of response, non-response, and progression into experimental studies that define mechanisms and inform novel therapeutic targets and/or combination strategies.
Data Integration: Integrate experimental results with clinical, biomarker, and computational datasets to generate actionable insights.
Capability Building: Establish and evolve internal workflows, evaluate new technologies, mentor scientists, and manage external research partners as needed.
Required Skills, Experience & Education:
PhD, MD, or equivalent advanced degree in cancer biology, molecular or cellular biology, biological engineering, translational sciences, or a related discipline, with 10+ years of relevant experience.
Deep expertise in oncology biology and demonstrated success connecting human disease or clinical observations to experimental models and drug-development hypotheses.
Strong knowledge of targeted therapy, oncogenic signaling, and mechanisms of drug response and resistance; experience in RAS-driven cancers is highly desirable.
Experience with functional genomics and high-dimensional profiling technologies, including single-cell, spatial, or integrated multiomic approaches.
Proven ability to lead cross-functional research, influence strategy, and communicate clear, decision-oriented recommendations.
Preferred Skills:
Experience establishing or scaling laboratory-based reverse translation or translational research capabilities in biotechnology or pharmaceutical settings.
Hands-on experience with patient-derived specimens or models, perturbational studies, and validation of biomarkers or resistance mechanisms.
Breadth across tumor-intrinsic and tumor-microenvironment biology and experience integrating experimental and computational data.
#LI-NE1 #LI-Hybrid
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Skills Required
- PhD, MD, or equivalent advanced degree in cancer biology, molecular or cellular biology, biological engineering, translational sciences, or related discipline with 10+ years relevant experience.
- Deep expertise in oncology biology and demonstrated success connecting human disease or clinical observations to experimental models and drug-development hypotheses.
- Strong knowledge of targeted therapy, oncogenic signaling, and mechanisms of drug response and resistance.
- Experience with functional genomics and high-dimensional profiling technologies, including single-cell, spatial, or integrated multiomic approaches.
- Proven ability to lead cross-functional research, influence strategy, and communicate clear, decision-oriented recommendations.
- Experience in RAS-driven cancers.
- Experience establishing or scaling laboratory-based reverse translation or translational research capabilities in biotech or pharma.
- Hands-on experience with patient-derived specimens or models, perturbational studies, and biomarker or resistance mechanism validation.
- Breadth across tumor-intrinsic and tumor-microenvironment biology and experience integrating experimental and computational data.
What We Do
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses
